These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 35542993)
41. Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria. Togher Z; Dolphin H; Russell C; Ryan M; Kennelly SP; O'Dowd S Int J Geriatr Psychiatry; 2022 Aug; 37(8):. PubMed ID: 35861223 [TBL] [Abstract][Full Text] [Related]
42. A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies. Wasielewska JM; Chaves JCS; Johnston RL; Milton LA; Hernández D; Chen L; Song J; Lee W; Leinenga G; Nisbet RM; Pébay A; Götz J; White AR; Oikari LE Theranostics; 2022; 12(16):6826-6847. PubMed ID: 36276649 [No Abstract] [Full Text] [Related]
43. Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy. Sotoudeh H; Alizadeh M; Shahidi R; Shobeiri P; Saadatpour Z; Wheeler CA; Natelson Love M; Tanwar M Front Radiol; 2023; 3():1305390. PubMed ID: 38249159 [TBL] [Abstract][Full Text] [Related]
44. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle. Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697 [TBL] [Abstract][Full Text] [Related]
47. Aducanumab: First Approval. Dhillon S Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167 [TBL] [Abstract][Full Text] [Related]
48. Aducanumab for Alzheimer's disease: A regulatory perspective. Nisticò R; Borg JJ Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830 [TBL] [Abstract][Full Text] [Related]
49. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease. Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577 [TBL] [Abstract][Full Text] [Related]
50. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis. Terao I; Honyashiki M; Inoue T Ageing Res Rev; 2022 Nov; 81():101709. PubMed ID: 35961514 [TBL] [Abstract][Full Text] [Related]
51. Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease. Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P Neurol Ther; 2021 Dec; 10(2):919-940. PubMed ID: 34426940 [TBL] [Abstract][Full Text] [Related]
52. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review. Haddad HW; Malone GW; Comardelle NJ; Degueure AE; Kaye AM; Kaye AD Health Psychol Res; 2022; 10(1):31925. PubMed ID: 35928986 [TBL] [Abstract][Full Text] [Related]
53. Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease. Ryan NS; Lashley T; Revesz T; Dantu K; Fox NC; Morris HR J Alzheimers Dis; 2015; 44(4):1069-74. PubMed ID: 25408217 [TBL] [Abstract][Full Text] [Related]
55. Making the Case for the Accelerated Withdrawal of Aducanumab. Whitehouse PJ; Saini V J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796 [TBL] [Abstract][Full Text] [Related]
56. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage. Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329 [TBL] [Abstract][Full Text] [Related]
57. Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Aβ Autoantibodies. Piazza F; Caminiti SP; Zedde M; Presotto L; DiFrancesco JC; Pascarella R; Giossi A; Sessa M; Poli L; Basso G; Perani D Neurology; 2022 Sep; 99(12):e1265-e1277. PubMed ID: 35940900 [TBL] [Abstract][Full Text] [Related]
58. Amyloid-Related Imaging Abnormalities: An Update. Roytman M; Mashriqi F; Al-Tawil K; Schulz PE; Zaharchuk G; Benzinger TLS; Franceschi AM AJR Am J Roentgenol; 2023 Apr; 220(4):562-574. PubMed ID: 36321981 [TBL] [Abstract][Full Text] [Related]
59. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. Mukhopadhyay S; Banerjee D J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359 [TBL] [Abstract][Full Text] [Related]
60. Aducanumab for the treatment of Alzheimer's disease. Tagliapietra M Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]